Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 7 | 2024 | 286 | 2.390 |
Why?
|
| Radiotherapy, Image-Guided | 4 | 2025 | 62 | 1.130 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 1061 | 1.100 |
Why?
|
| Metals | 2 | 2016 | 99 | 0.990 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2016 | 67 | 0.990 |
Why?
|
| Fiducial Markers | 2 | 2025 | 10 | 0.920 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 188 | 0.830 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.800 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 304 | 0.790 |
Why?
|
| Pneumonia | 1 | 2022 | 184 | 0.710 |
Why?
|
| Phantoms, Imaging | 2 | 2020 | 466 | 0.660 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2017 | 367 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 962 | 0.600 |
Why?
|
| Artifacts | 2 | 2016 | 246 | 0.580 |
Why?
|
| Movement | 1 | 2020 | 315 | 0.570 |
Why?
|
| Dental Restoration, Permanent | 1 | 2016 | 2 | 0.540 |
Why?
|
| Dental Implants | 1 | 2016 | 11 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 1129 | 0.530 |
Why?
|
| Software | 1 | 2020 | 670 | 0.500 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2370 | 0.490 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1229 | 0.440 |
Why?
|
| Prostatic Neoplasms | 2 | 2025 | 1751 | 0.410 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2025 | 176 | 0.400 |
Why?
|
| Neoplasms | 3 | 2024 | 3030 | 0.380 |
Why?
|
| Algorithms | 2 | 2016 | 1919 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1096 | 0.340 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2025 | 1259 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2025 | 2705 | 0.280 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 47 | 0.280 |
Why?
|
| Radiation Oncology | 2 | 2020 | 122 | 0.270 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 2019 | 0.260 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1066 | 0.260 |
Why?
|
| Humans | 17 | 2025 | 90640 | 0.230 |
Why?
|
| Organs at Risk | 2 | 2025 | 43 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 604 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 65 | 0.220 |
Why?
|
| Radiotherapy Dosage | 2 | 2025 | 468 | 0.210 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1709 | 0.210 |
Why?
|
| Cetuximab | 1 | 2022 | 116 | 0.190 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 112 | 0.180 |
Why?
|
| Odontogenic Tumors | 1 | 2020 | 12 | 0.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 43 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2022 | 875 | 0.180 |
Why?
|
| Aged | 6 | 2025 | 19424 | 0.180 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 82 | 0.170 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 80 | 0.170 |
Why?
|
| Male | 8 | 2025 | 42967 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2022 | 702 | 0.160 |
Why?
|
| Cystectomy | 2 | 2017 | 106 | 0.160 |
Why?
|
| Radiotherapy | 2 | 2020 | 318 | 0.160 |
Why?
|
| Cytokines | 1 | 2023 | 814 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 854 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6816 | 0.150 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 1170 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 321 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2024 | 4348 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 760 | 0.140 |
Why?
|
| Carcinoma | 1 | 2020 | 438 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2021 | 9330 | 0.140 |
Why?
|
| Oncologists | 1 | 2017 | 38 | 0.140 |
Why?
|
| Radiation Oncologists | 1 | 2016 | 15 | 0.130 |
Why?
|
| Propensity Score | 1 | 2017 | 154 | 0.130 |
Why?
|
| Middle Aged | 6 | 2025 | 26347 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2020 | 591 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 220 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8379 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 291 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 185 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2017 | 152 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2025 | 2891 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 570 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2017 | 898 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2017 | 249 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 841 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 615 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 982 | 0.120 |
Why?
|
| Female | 6 | 2024 | 46894 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1500 | 0.110 |
Why?
|
| Prognosis | 2 | 2021 | 3813 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 466 | 0.110 |
Why?
|
| Adult | 4 | 2024 | 26953 | 0.100 |
Why?
|
| Time Factors | 1 | 2020 | 5366 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2338 | 0.080 |
Why?
|
| United States | 4 | 2020 | 7142 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 152 | 0.050 |
Why?
|
| Physics | 1 | 2020 | 21 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 316 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 222 | 0.040 |
Why?
|
| Research | 1 | 2020 | 252 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 198 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 498 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 283 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 280 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 955 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1251 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 360 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 850 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1871 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3698 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1549 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5583 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2670 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 2525 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6426 | 0.010 |
Why?
|